Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125906412 | 12590641 | 2 | F | 20141210 | 20160803 | 20160726 | 20160805 | EXP | FR-ROCHE-1800394 | ROCHE | 4.00 | YR | M | Y | 15.00000 | KG | 20160805 | MD | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125906412 | 12590641 | 1 | PS | RoValcyte | VALGANCICLOVIR HYDROCHLORIDE | 1 | Oral | Y | 21304 | 6 | ML | QD | |||||||
| 125906412 | 12590641 | 2 | SS | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Oral | Y | 0 | 140 | ML | ORAL SUSPENSION | QD | ||||||
| 125906412 | 12590641 | 3 | SS | EUPANTOL | PANTOPRAZOLE SODIUM | 1 | Oral | Y | 0 | .75 | DF | QD | |||||||
| 125906412 | 12590641 | 4 | SS | LOVENOX | ENOXAPARIN SODIUM | 1 | Subcutaneous | Y | 0 | 700 | IU | QD | |||||||
| 125906412 | 12590641 | 5 | C | ASPEGIC | ASPIRIN DL-LYSINE | 1 | Oral | 0 | 100 | MG | |||||||||
| 125906412 | 12590641 | 6 | C | ASPEGIC | ASPIRIN DL-LYSINE | 1 | Oral | 0 | 100 | MG | |||||||||
| 125906412 | 12590641 | 7 | C | NEORAL | CYCLOSPORINE | 1 | Oral | 0 | 70 | MG | BID | ||||||||
| 125906412 | 12590641 | 8 | C | CELLCEPT | MYCOPHENOLATE MOFETILMYCOPHENOLATE MOFETIL HYDROCHLORIDE | 1 | Oral | 0 | 500 | MG | QD | ||||||||
| 125906412 | 12590641 | 9 | C | ENALAPRIL | ENALAPRIL | 1 | Oral | 0 | .25 | DF | QD | ||||||||
| 125906412 | 12590641 | 10 | C | PHOSPHONEUROS | CALCIUM PHOSPHATE, DIBASIC, ANHYDROUSMAGNESIUM GLYCEROPHOSPHATEPHOSPHORIC ACIDSODIUM PHOSPHATE, DIBASIC | 1 | Oral | 0 | 10 | GTT | QD | ||||||||
| 125906412 | 12590641 | 11 | C | FUNGIZONE | AMPHOTERICIN B | 1 | Oral | 0 | 250 | MG | TID | ||||||||
| 125906412 | 12590641 | 12 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | Oral | 0 | 5 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125906412 | 12590641 | 1 | Antiviral prophylaxis |
| 125906412 | 12590641 | 2 | Antibiotic prophylaxis |
| 125906412 | 12590641 | 3 | Prophylaxis against gastrointestinal ulcer |
| 125906412 | 12590641 | 4 | Thrombosis prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125906412 | 12590641 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125906412 | 12590641 | Hepatocellular injury |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125906412 | 12590641 | 1 | 20141208 | 20141211 | 0 | |
| 125906412 | 12590641 | 2 | 20141207 | 20141211 | 0 | |
| 125906412 | 12590641 | 3 | 20141209 | 20141214 | 0 | |
| 125906412 | 12590641 | 4 | 20141207 | 20141213 | 0 | |
| 125906412 | 12590641 | 5 | 20141209 | 20141215 | 0 | |
| 125906412 | 12590641 | 6 | 20141227 | 0 | ||
| 125906412 | 12590641 | 7 | 20141207 | 0 | ||
| 125906412 | 12590641 | 8 | 20141208 | 0 | ||
| 125906412 | 12590641 | 9 | 20141210 | 0 | ||
| 125906412 | 12590641 | 10 | 20141210 | 20141214 | 0 | |
| 125906412 | 12590641 | 11 | 20141207 | 0 | ||
| 125906412 | 12590641 | 12 | 20141208 | 0 |